To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Dermatology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00403-022-02468-3.pdf
Reference40 articles.
1. Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME (2017) Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol 153(7):694–697
2. Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, Lacouture M, Kraehenbuehl L, Stratigos A, Peris K, Lazaridou E, Richert B, Vigarios E, Riganti J, Baroudjian B, Filoni A, Dodiuk-Gad R, Lebbé C, Sibaud V (2022) European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force “Dermatology for cancer patients” position statement. J Eur Acad Dermatol Venereol 36(3):332–350
3. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073–4126
4. Antonov NK, Nair KG, Halasz CL (2019) Transient eruptive keratoacanthomas associated with nivolumab. JAAD Case Rep 5(4):342–345
5. Bandino JP, Perry DM, Clarke CE, Marchell RM, Elston DM (2017) Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology. J Eur Acad Dermatol Venereol 31(8):e378–e380
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Delayed onset eruptive keratoacanthomas following immune checkpoint inhibitor therapy;International Journal of Dermatology;2024-09-11
2. Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use;JAMA Dermatology;2024-05-01
3. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy;Journal for ImmunoTherapy of Cancer;2024-04
4. A Fortunate Eruption of Malignancies: Nivolumab-Induced Squamous Cell Carcinomas;EURASIAN J MED ONCOL;2024
5. Multiple Eruptive Keratoacanthomas Secondary to Nivolumab Immunotherapy;Journal of Immunotherapy;2023-11-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3